Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

OBJECTIVE: Aspirin is a widely used drug for prevention of thrombotic events in cardiovascular patients, but approximately 25% of patients experience insufficient platelet inhibition due to aspirin, and remain in risk of cardiovascular events. This study aimed to investigate the value of circulating miR-92a and platelet size as biomarkers of the individual response to aspirin therapy.

METHODS: Blood samples were collected from 50 healthy blood donors without antithrombotic medication and 50 patients with intermittent claudication on daily aspirin therapy. Based on results from the arachidonic acid stimulated aggregation test on Multiplate®analyzer (ASPItest), patients were defined as aspirin resistant (n=10) or aspirin responders (n=40). Plasma levels of miR-92a were evaluated by RT-qPCR analysis and platelet distribution width (PDW) was used to assess platelet size variability. Receiver operating characteristic curves for miR-92a levels and PDW were used to set cut-off values for discrimination between aspirin responding and aspirin resistant patients.

RESULTS: When defining aspirin resistance as an ASPItest ≥30U, the optimal cut-off values for discrimination of aspirin responders and aspirin resistant patients were found to be PDW>11.8fL and a relative expression level of miR-92a>4.5. Using these cut-off values we could define a PDW/miR-92a-score with a specificity of 97.5% and a sensitivity of 80.0% in relation to detect aspirin resistance. The corresponding positive and negative predictive values were found to be 88.9% and 95.1%, respectively.

CONCLUSION: Aspirin resistance can potentially be identified by miR-92a levels in plasma combined with PDW.

Original languageEnglish
JournalClinical Biochemistry
Volume49
Issue number15
Pages (from-to)1167-1172
ISSN0009-9120
DOIs
Publication statusPublished - 2016

Fingerprint

Platelets
Aspirin
Plasmas
Blood
Intermittent Claudication
Biomarkers
Arachidonic Acid
ROC Curve
Agglomeration

Cite this

@article{2d3ef37c4c3548d282cd8e9a1a1ec0ba,
title = "Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width",
abstract = "OBJECTIVE: Aspirin is a widely used drug for prevention of thrombotic events in cardiovascular patients, but approximately 25{\%} of patients experience insufficient platelet inhibition due to aspirin, and remain in risk of cardiovascular events. This study aimed to investigate the value of circulating miR-92a and platelet size as biomarkers of the individual response to aspirin therapy.METHODS: Blood samples were collected from 50 healthy blood donors without antithrombotic medication and 50 patients with intermittent claudication on daily aspirin therapy. Based on results from the arachidonic acid stimulated aggregation test on Multiplate{\circledR}analyzer (ASPItest), patients were defined as aspirin resistant (n=10) or aspirin responders (n=40). Plasma levels of miR-92a were evaluated by RT-qPCR analysis and platelet distribution width (PDW) was used to assess platelet size variability. Receiver operating characteristic curves for miR-92a levels and PDW were used to set cut-off values for discrimination between aspirin responding and aspirin resistant patients.RESULTS: When defining aspirin resistance as an ASPItest ≥30U, the optimal cut-off values for discrimination of aspirin responders and aspirin resistant patients were found to be PDW>11.8fL and a relative expression level of miR-92a>4.5. Using these cut-off values we could define a PDW/miR-92a-score with a specificity of 97.5{\%} and a sensitivity of 80.0{\%} in relation to detect aspirin resistance. The corresponding positive and negative predictive values were found to be 88.9{\%} and 95.1{\%}, respectively.CONCLUSION: Aspirin resistance can potentially be identified by miR-92a levels in plasma combined with PDW.",
author = "Binderup, {Helle Glud} and Kim Houlind and Madsen, {Jonna Skov} and Brasen, {Claus Lohman}",
note = "Copyright {\circledC} 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.",
year = "2016",
doi = "10.1016/j.clinbiochem.2016.04.017",
language = "English",
volume = "49",
pages = "1167--1172",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier",
number = "15",

}

Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. / Binderup, Helle Glud; Houlind, Kim; Madsen, Jonna Skov; Brasen, Claus Lohman.

In: Clinical Biochemistry, Vol. 49, No. 15, 2016, p. 1167-1172.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width

AU - Binderup, Helle Glud

AU - Houlind, Kim

AU - Madsen, Jonna Skov

AU - Brasen, Claus Lohman

N1 - Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE: Aspirin is a widely used drug for prevention of thrombotic events in cardiovascular patients, but approximately 25% of patients experience insufficient platelet inhibition due to aspirin, and remain in risk of cardiovascular events. This study aimed to investigate the value of circulating miR-92a and platelet size as biomarkers of the individual response to aspirin therapy.METHODS: Blood samples were collected from 50 healthy blood donors without antithrombotic medication and 50 patients with intermittent claudication on daily aspirin therapy. Based on results from the arachidonic acid stimulated aggregation test on Multiplate®analyzer (ASPItest), patients were defined as aspirin resistant (n=10) or aspirin responders (n=40). Plasma levels of miR-92a were evaluated by RT-qPCR analysis and platelet distribution width (PDW) was used to assess platelet size variability. Receiver operating characteristic curves for miR-92a levels and PDW were used to set cut-off values for discrimination between aspirin responding and aspirin resistant patients.RESULTS: When defining aspirin resistance as an ASPItest ≥30U, the optimal cut-off values for discrimination of aspirin responders and aspirin resistant patients were found to be PDW>11.8fL and a relative expression level of miR-92a>4.5. Using these cut-off values we could define a PDW/miR-92a-score with a specificity of 97.5% and a sensitivity of 80.0% in relation to detect aspirin resistance. The corresponding positive and negative predictive values were found to be 88.9% and 95.1%, respectively.CONCLUSION: Aspirin resistance can potentially be identified by miR-92a levels in plasma combined with PDW.

AB - OBJECTIVE: Aspirin is a widely used drug for prevention of thrombotic events in cardiovascular patients, but approximately 25% of patients experience insufficient platelet inhibition due to aspirin, and remain in risk of cardiovascular events. This study aimed to investigate the value of circulating miR-92a and platelet size as biomarkers of the individual response to aspirin therapy.METHODS: Blood samples were collected from 50 healthy blood donors without antithrombotic medication and 50 patients with intermittent claudication on daily aspirin therapy. Based on results from the arachidonic acid stimulated aggregation test on Multiplate®analyzer (ASPItest), patients were defined as aspirin resistant (n=10) or aspirin responders (n=40). Plasma levels of miR-92a were evaluated by RT-qPCR analysis and platelet distribution width (PDW) was used to assess platelet size variability. Receiver operating characteristic curves for miR-92a levels and PDW were used to set cut-off values for discrimination between aspirin responding and aspirin resistant patients.RESULTS: When defining aspirin resistance as an ASPItest ≥30U, the optimal cut-off values for discrimination of aspirin responders and aspirin resistant patients were found to be PDW>11.8fL and a relative expression level of miR-92a>4.5. Using these cut-off values we could define a PDW/miR-92a-score with a specificity of 97.5% and a sensitivity of 80.0% in relation to detect aspirin resistance. The corresponding positive and negative predictive values were found to be 88.9% and 95.1%, respectively.CONCLUSION: Aspirin resistance can potentially be identified by miR-92a levels in plasma combined with PDW.

U2 - 10.1016/j.clinbiochem.2016.04.017

DO - 10.1016/j.clinbiochem.2016.04.017

M3 - Journal article

C2 - 27208561

VL - 49

SP - 1167

EP - 1172

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 15

ER -